RYE BROOK, N.Y.--(BUSINESS WIRE)--SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site. The investment is supported by $21 million in state and local incentive awards and will expand SCHOTT Group’s presence in the United States, a strategic market in its growth plan.

纽约州莱伊布鲁克（商业新闻短讯）--肖特制药公司计划在北卡罗来纳州的威尔逊建立其最新网站。这项投资得到了2100万美元的州和地方激励奖的支持，并将扩大肖特集团在美国的业务，美国是其增长计划中的战略市场。

SCHOTT Pharma, a pioneer in pharmaceutical drug containment solutions and delivery systems, will build the first U.S. facility to manufacture prefillable polymer syringes required to meet the need for deep-cold storage and transportation of mRNA medications. In addition, the site will have the capability to produce glass prefillable syringes for GLP-1 therapies, for example to treat diseases such as diabetes or obesity.

肖特制药（SCHOTT Pharma）是药物控制解决方案和输送系统的先驱，它将建造美国第一家生产可预填充聚合物注射器的工厂，以满足mRNA药物深度冷藏和运输的需要。此外，该网站将有能力生产用于GLP-1治疗的玻璃预填充注射器，例如用于治疗糖尿病或肥胖症等疾病。

The project will add 401 jobs to the region and include a total investment of $371 million, with groundbreaking expected by the end of 2024, and projected operations starting in 2027..

该项目将为该地区增加401个就业岗位，总投资3.71亿美元，预计2024年底将破土动工，预计2027年开始运营。。

The new site will expand the U.S. supply chain for in-demand syringes that deliver lifesaving injectable medicines, vaccines, and other fields of applications, allowing SCHOTT Pharma to triple its contribution of glass and polymer syringes to the U.S. market by 2030. Bringing production to the U.S. will reduce lead times and slash transportation costs, as well as protect against future shortages of critical drugs and ensure pandemic preparedness..

该新工厂将扩大美国需求注射器的供应链，这些注射器可提供救生注射药物、疫苗和其他应用领域，使肖特制药公司到2030年将玻璃和聚合物注射器在美国市场的贡献增加三倍。将生产带到美国将缩短交付周期，降低运输成本，并防止未来关键药物短缺，确保大流行防范。。

“As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies that require precise drug stability and storage properties, SCHOTT Pharma will be able to fill those orders quickly and efficiently here in the U.S.,” said Andreas Reisse, CEO of SCHOTT Pharma. “The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain.”.

肖特制药首席执行官安德烈亚斯·赖斯（AndreasReisse）表示：“随着药物制造商开发和扩大mRNA、GLP-1和其他需要精确药物稳定性和储存特性的生物疗法的使用，肖特制药将能够在美国快速有效地完成这些订单。”。“该设施的影响将远远超出北卡罗莱纳州当地创造的就业机会，并将缓解整个制药行业供应链的压力。”。

The top 30 global pharma companies and more than 1,800 customers rely on SCHOTT Pharma containers and systems, including the U.S. and global leaders in the pharmaceutical and biotech categories. Many of these companies have designated SCHOTT Pharma as a critical supplier of one or more of the most essential components within their supply chain.

全球前30家制药公司和1800多家客户依赖肖特制药容器和系统，其中包括制药和生物技术领域的美国和全球领导者。其中许多公司已指定肖特制药（SCHOTT Pharma）为其供应链中一个或多个最重要组件的关键供应商。

On average, more than 25,000 injections per minute are provided to patients worldwide through a product produced by SCHOTT Pharma..

通过肖特制药公司生产的产品，平均每分钟向全世界的患者提供超过25000次注射。。

“Wilson County stood out in a nationwide search for a number of reasons, particularly for its favorable pool of local talent and its proximity to the Research Triangle area, which hosts numerous universities, healthcare companies, and biopharma resources,” said Christopher Cassidy, President of SCHOTT North America.

肖特北美公司总裁克里斯托弗·卡西迪（ChristopherCassidy）表示：“威尔逊县在全国范围内脱颖而出，原因有很多，特别是它拥有良好的当地人才库，并且靠近研究三角区，该地区拥有众多大学、医疗保健公司和生物制药资源。”。

“Expanding operations in the U.S. addresses rapidly growing demand for our high-value solutions.”.

“扩大在美国的业务可以满足对我们高价值解决方案快速增长的需求。”。

“North Carolina’s pro-growth and low-tax policies, along with the $40 million investment in the new biologics training facility at Wilson Community College, are paying off for Wilson County and the BioPharma Crescent,” said North Carolina Senator Buck Newton. “SCHOTT Pharma’s $371 million capital investment and 401 high-wage jobs will strengthen our local economy.

北卡罗莱纳州参议员巴克·牛顿说：“北卡罗莱纳州的促增长和低税收政策，以及对威尔逊社区学院新生物制剂培训设施的4000万美元投资，正在为威尔逊县和生物制药新月会带来回报。”。“肖特制药（SCHOTT Pharma）3.71亿美元的资本投资和401份高薪工作将加强我们当地的经济。

We look forward to a long and successful future for them here in Wilson.”.

我们期待着他们在威尔逊拥有一个漫长而成功的未来。”。

For over two decades, SCHOTT Pharma has been manufacturing vials at its Lebanon, PA, facility, serving as a reliable partner for the pharmaceutical industry. Being that the U.S. is a key strategic market for the entire SCHOTT Group, the company underwent a nationwide site selection process for a campus-like property to serve further growth opportunities.

二十多年来，肖特制药一直在其位于宾夕法尼亚州黎巴嫩的工厂生产小瓶，是制药行业可靠的合作伙伴。由于美国是整个肖特集团的关键战略市场，该公司在全国范围内进行了选址，以打造校园式物业，为进一步的发展机会服务。

While SCHOTT is not guaranteeing additional investment to support other markets at this time, the site in Wilson, North Carolina offers the possibility of future expansion..

虽然肖特目前不保证额外投资来支持其他市场，但位于北卡罗莱纳州威尔逊的网站提供了未来扩张的可能性。。

The project location is contingent on final real estate negotiations. SCHOTT Pharma partnered with several organizations throughout the project, including the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina, the North Carolina General Assembly, the North Carolina Community College System, Commerce’s Division of Workforce Solutions, Wilson County, the City of Wilson, the Wilson Economic Development Council, the North Carolina Biotechnology Center, and the Biomanufacturing Training and Education Center at North Carolina State University..

项目位置取决于最终的房地产谈判。肖特制药在整个项目中与多个组织合作，包括北卡罗莱纳州商务部和北卡罗莱纳州经济发展伙伴关系、北卡罗莱纳州大会、北卡罗莱纳州社区学院系统、商业劳动力解决方案部、威尔逊县、威尔逊市、威尔逊经济发展委员会，北卡罗莱纳州生物技术中心和北卡罗莱纳州立大学生物制造培训和教育中心。。

About SCHOTT Pharma

关于肖特制药

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from pre-fillable glass and polymer syringes to cartridges, vials, and ampoules.

人类健康很重要。这就是为什么肖特制药（SCHOTT Pharma）以科学为基础设计解决方案，以确保药物对世界各地的人们安全且易于使用。该组合包括用于注射药物的药物遏制解决方案和输送系统，从预填充玻璃和聚合物注射器到药筒，小瓶和安瓿。

Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future.

肖特制药（SCHOTT Pharma）每天都有来自60多个国家的4600多人组成的团队为全球医疗保健做出贡献。该公司在欧洲、北美、南美和亚洲的所有主要制药中心拥有16个生产基地。该公司拥有1000多项内部开发的专利和技术，并在瑞士设有最先进的研发中心，专注于为未来开发创新。

SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030.

肖特制药股份有限公司KGaA总部位于德国美因茨，作为SDAX的一部分在法兰克福证券交易所上市。它是由卡尔·蔡司基金会拥有的肖特公司的一部分。本着这种精神，肖特制药致力于社会和环境的可持续发展，并制定了到2030年实现气候中性的战略目标。

Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023. Further information at schott-pharma.com..

目前，肖特制药拥有1800多家客户，其中包括前30家领先的注射剂制药制造商，2023财年的收入为8.99亿欧元。更多信息请访问schott pharma.com。。

About SCHOTT

关于肖特

International technology group SCHOTT produces high-quality components and advanced materials, including specialty glass, glass-ceramics, and polymers. Many SCHOTT products have high-tech applications that push technological boundaries, such as flexible glass in foldable smartphones, glass-ceramic mirror substrates in the world's largest telescopes, and laser glass in nuclear fusion.

国际科技集团肖特生产高品质部件和先进材料，包括特种玻璃、微晶玻璃和聚合物。肖特（SCHOTT）的许多产品具有推动技术边界的高科技应用，例如可折叠智能手机中的柔性玻璃、世界最大望远镜中的微晶玻璃镜面基板以及核聚变中的激光玻璃。

With their pioneering spirit, approximately 17,100 SCHOTT employees in over 30 countries work as partners to industries such as healthcare, home appliances, consumer electronics, semiconductors, optics, astronomy, energy, and aerospace. In fiscal year 2023, SCHOTT generated 3 billion USD in sales. In addition to innovation, one of its important corporate goals is sustainability, where it is pursuing climate neutral production by 2030.

凭借他们的开拓精神，肖特在30多个国家的约17100名员工成为医疗保健、家用电器、消费电子、半导体、光学、天文、能源和航空航天等行业的合作伙伴。2023财年，肖特的销售额达到30亿美元。除了创新之外，其重要的企业目标之一是可持续性，即到2030年实现气候中性生产。

SCHOTT was founded in 1884 and is headquartered in Mainz, Germany. The company belongs to the Carl Zeiss Foundation, which uses its dividends to promote science. Further information at schott.com..

肖特成立于1884年，总部位于德国美因茨。该公司隶属于卡尔·蔡司基金会，该基金会利用其股息促进科学发展。更多信息请访问肖特网。。